Synagis 100 mg

SYNAGIS 100 MG is a solution used for respiratory syncytial virus (RSV) prevention. This medication, containing palivizumab, is administered intramuscularly to reduce the risk of severe RSV infections in high-risk individuals.

SYNAGIS 100 MG is primarily used for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV). It is often prescribed for individuals at high risk of severe RSV infections, such as premature infants or those with chronic lung disease. The medication works by neutralizing the RSV virus, helping to protect vulnerable patients during RSV season.

Common effects of SYNAGIS 100 MG may include mild redness, swelling, or pain at the injection site. Some individuals might experience fever, irritability, or mild gastrointestinal discomfort. These effects are generally temporary and resolve on their own. Severe reactions are rare but should be reported to a healthcare provider immediately.

SYNAGIS 100 MG should be handled with care and stored as directed to maintain its efficacy. It is important to inform healthcare providers about any allergies or medical conditions before administration. The medication should be used under medical supervision, and any unusual symptoms should be reported promptly.

SYNAGIS 100 MG may interact with other medications, particularly those that affect the immune system. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of the medication, so caution is recommended.